Foghorn Therapeutics (FHTX) Other Accumulated Expenses (2020 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Other Accumulated Expenses came in at $437000.0 in Q1 2026, down 16.92% year-on-year from $526000.0 in Q1 2025, and up 9.25% quarter-over-quarter from $400000.0 in Q4 2025.
Foghorn Therapeutics (FHTX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $437000.0 for Q1 2026.
- On a quarterly basis, Other Accumulated Expenses fell 16.92% year-over-year to $437000.0 in Q1 2026; TTM through Mar 2026 was $437000.0, a 16.92% decrease from a year earlier, with the FY2025 full-year figure at $400000.0, up 39900.0% from the prior year.
- Other Accumulated Expenses rose to $437000.0 in Q1 2026 per FHTX's latest filing, from $400000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $526000.0 in Q1 2025 and bottomed at $1000.0 in Q4 2024.
- The 5-year median for Other Accumulated Expenses is $286500.0 (2022), against an average of $269625.0.
- Across the five-year window, Other Accumulated Expenses plunged 97.22% in 2024 and soared 39900.0% in 2025, its largest moves.
- Year by year, Other Accumulated Expenses stood at $318000.0 in 2022, then tumbled by 88.68% to $36000.0 in 2023, then plunged by 97.22% to $1000.0 in 2024, then surged by 39900.0% to $400000.0 in 2025, then gained by 9.25% to $437000.0 in 2026.
- Per Business Quant, the three latest FHTX Other Accumulated Expenses figures stand at $437000.0 (Q1 2026), $400000.0 (Q4 2025), and $396000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 437,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 396,000.00 |
| Jun 30, 2025 | 392,000.00 |
| Mar 31, 2025 | 526,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 213,000.00 |
| Jun 30, 2024 | 239,000.00 |
| Dec 31, 2023 | 36,000.00 |
| Sep 30, 2023 | 301,000.00 |
| Jun 30, 2023 | 94,000.00 |
| Mar 31, 2023 | 135,000.00 |
| Dec 31, 2022 | 318,000.00 |
| Sep 30, 2022 | 324,000.00 |
| Jun 30, 2022 | 272,000.00 |
| Mar 31, 2022 | 230,000.00 |
| Dec 31, 2021 | 392,000.00 |
| Sep 30, 2021 | 108,000.00 |
| Dec 31, 2020 | 138,000.00 |